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KuwaitAbstract Background: Interstitial lung disease (ILD) is a frequent extra-articular manifestation of
RA and can cause signiﬁcant morbidity and mortality.
Aim of the work: To characterize and deﬁne the frequency of radiological and functional abnor-
malities capable of identifying ‘‘subclinical’’ RA-ILD with particular concern to the effect of
methotrexate (MTX) therapy.
Patients and methods: Sixty patients with RA were recruited with no respiratory manifestations.
They were classiﬁed into two groups: group 1 included 35 patients receiving MTX and group 2
included 25 patients receiving only nonsteroidal anti-inﬂammatory drugs. Patients were also classi-
ﬁed according to chest high resolution CT (HRCT) as RA-ILD or RA-noILD. Pulmonary function
test (PFT) abnormalities were also used to further characterize occult respiratory defects.
Results: 38.3% of RA patients had subclinical ILD (25% in group 1 and 13.3% in group 2),
while 61.7% were RA-no ILD. The percentage of patients with RA-ILD was insigniﬁcantly more
in group 1 than group 2 (42.9% and 32% respectively). HRCT score revealed minimal to mild
involvement in both groups. Long-standing RA with mean articular duration >50 months carries
a signiﬁcant risk for ILD. Other variables as age, gender, smoking, disease activity or rheumatoid
factor seropositivity were not signiﬁcant risk factors for development of RA-ILD.
78 N.K. Affara et al.Conclusions: Lung involvement should always be considered in patients with RA particularly
those on MTX therapy even in the absence of chest symptoms. A tight control by PFTs, chest
radiography and/or HRCT is necessary. Further studies evaluating the potential effect of MTX
on progressive ILD with RA are needed.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is one of the most common and
serious forms of arthritis. It is a chronic inﬂammatory autoim-
mune disease, mainly characterized by inﬂammation of the lin-
ing synovium of the joints with long-term joint destruction,
leading to severe disability and premature mortality [1]. The
presence of auto antibodies, such as rheumatoid factor (RF)
and anti-cyclic citrullinated peptide (anti-CCP) can precede
the clinical manifestation of RA by many years [2].
It has been estimated that nearly 50% of RA patients
develop some form of respiratory abnormality during their
lifetime. While there are numerous pulmonary complications
associated with RA, the most debilitating remains rheumatoid
arthritis-associated interstitial lung disease (RA-ILD) [3].
Advancements in imaging technology have improved our abil-
ity to diagnose RA-ILD, and what once was thought to be a
relatively rare complication is now suspected to affect
20–30% of RA patients [4].
Over the last decade, the optimal use of disease modifying
anti rheumatic drugs (DMARDs), in particular the anchor
DMARD methotrexate (MTX) [5], and the availability of
new biologic agents [6], have dramatically enhanced the suc-
cess of RA management. However patients with RA may
develop lung disease from these medications, with reports of
pulmonary toxicity from gold [7], penicillamine [8], bucil-
lamine [9], leﬂunomide [10], methotrexate [11], sulfasalazine
[12], and inﬂiximab [13]. MTX is the ﬁrst choice DMARD
for RA [14], which is a folic acid antagonist that inhibits cellu-
lar reproduction by causing an acute intracellular deﬁciency of
folate coenzymes. Two forms of interstitial lung disease related
to MTX therapy have been reported, life-threatening acute
MTX pneumonitis, which is the most feared complication
[15] and chronic pulmonary ﬁbrosis. As recently reported,
these side effects may be triggered by genetic factors; however,
hypersensitivity is probably responsible for most cases of pneu-
monitis associated with MTX, particularly in the cases with
established lung disease [16].
There is growing awareness that some forms of RA-ILD
transition from asymptomatic or ‘‘subclinical’’ stages before
an eventual clinical diagnosis. Subclinical ILD involves groups
of patients who have speciﬁc radiological, physiological and in
some cases histo-pathological abnormalities but are either
asymptomatic or have symptoms that have not been attributed
to ILD [17,18].
Little work has been conducted to show the preclinical and
early radiological and functional manifestations in asymp-
tomatic RA patients. So this study was done to characterize
and deﬁne the frequency of radiological and functional
abnormalities capable of identifying ‘‘subclinical’’ RA-ILD
with particular concern to the effect of MTX therapy.2. Patients and methods
This study was done at Alrashid Respiratory center and
Respiratory, Rheumatology& Radiology departments,
Farwaniya Hospital, Ministry of Health, State of Kuwait. 60
Kuwaiti patients with Rheumatoid arthritis (RA) were
recruited in the period between November 2012 and
February 2014 and were diagnosed with deﬁnite RA according
to the 2010 criteria of American College of Rheumatology [1].
All patients had no chest symptoms or signs at time of inclu-
sion. They were classiﬁed into two groups according to the
therapy use; Group (1) included 35 patients (58.3%) who
received only MTX therapy and Group (2) included 25
patients (41.7%) who received only non-steroidal anti-
inﬂammatory drugs (or cyclo-oxygenase enzyme-2 ‘COX-2’
inhibitors). All patients were also further classiﬁed into cate-
gories of RA-ILD and RA-no ILD based on HRCT abnor-
malities consisting of ground glass opacities (GGO), septal
lines, reticulations, subpleural ﬁbrosis, traction bronchiectasis,
architectural distortion, and/or honeycombing. The study was
approved by the ethics committee of the Ministry of Health,
State of Kuwait and the patients were included in the study
after giving their informed consent after explanation of the
purpose and procedures of the study.
All enrolled patients were subjected to complete history
taking and examination including duration of disease, smoking
status and drug therapy. Assessment of disease activity was
done using the Simpliﬁed Disease Activity Index (SDAI)
[19], which is the numerical sum of ﬁve outcome parameters,
tender and swollen joint count scores (based on a 28 points
joint assessment), patient and physician global assessment of
disease activity (visual analog scale (VAS) 0–10 cm) and level
of C-reactive protein (normal <1 mg/dl). A score of more than
26 points denotes high disease activity, from 11 to 26 points
indicates moderate disease activity and less than 11 denotes
low disease activity and less than 3 means disease remission
[11]. Laboratory investigations were done including complete
blood count (CBC), erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), Rheumatoid factor (RF) (IgG
Enhanced ELISA, ImmuLisa, Euro Diagnostica, Malmo,
Sweden), and anti-cyclic citrullinated peptide (anti-CCP)
(ELISA Kit, GenWay Biotech. Inc, San Diego, USA).
Complete pulmonary function testing (PFT) were made
using Jaeger Masterscreen PFT system (CareFusion,
Germany) and according to American Thoracic Society rec-
ommendations [12]. Measurement of the diffusing capacity
for carbon monoxide (DLCO, mL/min/mmHg) was performed
using Real-time DLCO gas analysis. We recorded the propor-
tions of patients presenting reduced total lung capacity
(TLC) or reduced forced vital capacity (FVC) lower than
80% of predicted with a normal or increased ratio between
Figure 1 Plain chest X-ray of an RA patient showing bilateral reticular shadows. The HRCT scans from same patients show bilateral
basal interstitial thickening with honeycombing (outlined arrows).
Figure 2 Plain chest X-ray of an RA patient showing bilateral reticular shadows and the HRCT scan from same patients shows right
basal interstitial thickening (white arrows) and areas of ground glass opacities (red arrows).
Figure 3 Abnormal chest radiography, PFT and HRCT in RA
patients on MTX (group 1) or on NSAIDs only (group 2).
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DLCO lower than 75% of predicted.
All patients were subjected to plain chest X-ray and high-
resolution computed tomography (HRCT) scan, which was
graded using a modiﬁed quantitative scale [20]. The ﬁndings
were assigned as 0; normal, 1; Minimal disease (3–4 septal
lines), 2; Mild (P5 septal lines, reticulations, subpleural cysts,
and ground glass opacities), 3; Moderate disease (grade 2 ﬁnd-
ings and traction bronchiectasis, peri-bronchovascular thick-
ening or tracheal retraction with one-third to two-thirds lung
involvement), or 4; Severe (grade 2 or 3 ﬁndings with more
than two-thirds lung involvement).2.1. Exclusion criteria
All patients under steroids or biological therapy, patients
known to have pulmonary or cardiovascular diseases, patients
with obstructive or mixed pulmonary dysfunction and those
Table 1 Baseline clinical and laboratory characteristics of RA
patient on MTX (group 1) or on NSAIDs only (group 2).
Characteristic RA patients (n= 60)
Group 1
(n= 35)
Group 2
(n= 25)
p
Age (years) 53 ± 14 56 ± 10 >0.05
Gender F:M 27:8 (3.4:1) 16:9 (1.8:1) >0.05
Smokers n (%) 9 (25.7) 8 (32) >0.05
Disease duration (months) 27.2 ± 5.2 20.5 ± 1 >0.05
Morning stiﬀness (min.) 80.3 ± 6 110 ± 3.4 >0.05
Swollen joint count (0–28) 4.3 ± 0.6 6.1 ± 0.7 >0.05
Tender joint count (0–28) 3.6 ± 0.7 8.5 ± 1.2 >0.05
PGA of pain (1–10) 3.7 ± 1.1 5.4 ± 0.1 >0.05
EGA of pain (1–10) 3.4 ± 0.8 4.6 ± 0.2 >0.05
SDAI 17.2 ± 5.7 12.5 ± 5.9 >0.05
RA: rheumatoid arthritis, group I: patients on methotrexate, group
2: patients on NSAIDs only. F:M: female to male ratio. PGA:
patient global assessment, EGA: evaluator global assessment,
SDAI: simple disease activity index. Results are presented as
mean ± SD except for gender presented as ratio and smokers as n
(%).
80 N.K. Affara et al.with active infection, HIV/AIDS, and malignancy were
excluded from the study.
2.2. Statistical analysis
Statistical analysis was done using statistical software ‘SPSS
version 10.0’ (SPSS Inc, Chicago, IL, USA). Normally dis-
tributed variables were summarized as mean with standard
deviation and compared between the two groups using
Student’s t-test. Chi-squared testing and Fisher exact test
was applied to compare the ordinal variables. For all analyses,
p value <0.05 was considered statistically signiﬁcant and p
value <0.001 was considered highly statistically signiﬁcant.
Multinomial logistic regression analysis was performed toTable 2 Radiological and pulmonary function tests abnormalities i
n (%) RA patie
Group 1
Abnormal CXR 8 (22.9)
Abnormal HRCT 15 (42.9)
HRCT abnormalities GGO 12 (34.3)
AS 5 (14.3)
Mixed AS/GGO 3 (8.6)
Honeycombing 4 (11.4)
Septal thickening 10 (28.6)
Traction bronchiectasis 4 (11.4)
Mean HRCT score 1.5
PFT (restrictive pattern) 11 (31.4)
Abnormal PFT FEV1 (<80% predicted) 7 (20)
FVC (<80% predicted) 9 (25.7)
TLC (<80% predicted) 11 (31.4)
DLCO (<75% predicted) 11 (31.4)
RA: rheumatoid arthritis, group I: patients on methotrexate, group 2
tomography, GGO: ground glass opacities, AS: airspace opacities, PFT: p
volume capacity, TLC: total lung capacity, DLco: diffusion capacity of cassess the relationship between the presence of ILD in patients
with RA (as a response variable) and a set of predictor vari-
ables. The regression coefﬁcients were actually computed by
a software program in terms of relative risk ratio and the
95% conﬁdence interval (95% CI).
3. Results
This study included 60 RA patients without respiratory symp-
toms. They were 43 females and 17 males with mean age
52.6 ± 5.1 years and disease duration of 26 ± 2.4 months.
Group 1 included those patients on MTX (mean dose
20.5 mg/week, mean duration 27.2 ± 5.2 months), and group
2 included 25 patients using only NSAIDs intermittently for
a mean duration of 20.5 ± 1 months. The baseline clinical
and laboratory of both groups are shown in Table 1 and all
showed no statistical signiﬁcant differences. In this study 23
patients (38.3%) had subclinical ILD (RA-ILD); 15 (65.2%)
patients were from group 1 and 8 from group 2 (34.8%), while
the remaining 37 patients (61.7%) did not meet the HRCT cri-
teria for diagnosing ILD and were therefore designated as RA-
no ILD. Table 2 shows that the percent of patients with RA-
ILD, as evident by the abnormalities in HRCT, was more in
group 1 than in group 2 (42.9% and 32% respectively), how-
ever this difference was insigniﬁcant. Ground glass opacities
and septal thickening were the most common (80.5% and
66.7% respectively) while honeycombing was observed in
62.7% of RA-ILD patients. HRCT score revealed minimal
to mild involvement in both groups (mean 1.5 vs 0.8,
p> 0.05). Patients in group 1 had more pulmonary dysfunc-
tion results in terms of lower means of percent predicted
FVC, TLC, FEV1, and DLCO, than those in group 2; though,
these differences were statistically insigniﬁcant (see Figs. 1–3).
Table 3 shows that 6/22 patients (27.2%) with short disease
duration (mean of 15 months) had HRCT evidence of ILD vs
17/38 patients (44.7%) with long disease duration (mean of
50 months); this difference was insigniﬁcant. Regarding PFT,
6 patients (27.2%) with short-disease duration had functionaln RA patient on MTX (group 1) or on NSAIDs only (group 2).
nts (n= 60)
(n= 35) Group 2 (n= 25) Total (n= 60) p
4 (16) 12 (20) >0.05
8 (32) 23 (38.3) >0.05
6 (24) 18 (30) >0.05
3 (12) 8 (13.3) >0.05
5 (20) 8 (13.3) >0.05
2 (8) 6 (10) >0.05
6 (24) 16 (26.7) >0.05
3 (12) 7 (11.7) >0.05
0.8 1.15 >0.05
5 (20) 16 (26.7) >0.05
4 (16) 11 (18.3) >0.05
5 (20) 14 (23.3) >0.05
5 (20) 16 (26.7) >0.05
5 (20) 16 (26.7) >0.05
: patients on NSAIDs only. HRCT: high resolution computerized
ulmonary function test, FEV: forced expiratory volume, FVC: forced
arbon monoxide.
Table 3 Radiological and PFT abnormalities among RA
patients as regards the disease duration.
Abnormalities
n (%)
RA patients according to their disease duration
(n= 60)
Long (n= 38)
(mean 50 months)
Short (n= 22)
(mean 15 months)
p
HRCT 17 (44.7) 6 (27.2) <0.05
PFT 10 (26.3) 6 (27.2) >0.05
Short disease duration: mean of 15 months, long disease duration:
mean of 50 months. HRCT: high resolution computerized tomog-
raphy, PFT: pulmonary function test.
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long-duration; this difference was insigniﬁcant. There was no
signiﬁcant difference in the dose or duration of MTX therapy
in patients with RA-ILD compared to those with RA-noILD
(p> 0.05).
Table 4 shows that, apart from the mean disease duration,
there were no signiﬁcant differences between RA-ILD patients
in either groups and those with RA-no ILD regarding clinical,
laboratory or functional data. Table 5 shows a multinomial
logistic regression analysis, which indicated a strong associa-
tion of ILD with age (>60; relative risk ratio, 4.31;
p< 0.05). Anti-CCP and RF titers showed a trend toward
association with ILD (relative risk ratio, 3.6 and 3.15 respec-
tively; p< 0.05). Age, gender, MTX intake, SDAI and smok-
ing were insigniﬁcantly associated with ILD (p> 0.05). The
presence of ILD was strongly associated with disease duration
(relative risk ratio, 7.67; p< 0.001). FVC < 80% of predi-
cated) showed a trend toward a negative association with
ILD (relative risk ratio, 3.98; p< 0.05).
4. Discussion
In the last years, it is becoming increasingly evident that RA-
ILD is a more prominent and debilitating manifestation of RA
than formerly believed. There are many factors that can
obscure the diagnosis, however early diagnosis and treatmentTable 4 Comparison of demographic features, disease activity, imm
Variable RA patients (n=
ILD n= 23 (38.3%
Gp1 (n= 15)
Age (years) 52.1 ± 10.7
Gender F:M 9:6 (1.5:1)
Smokers n (%) 5 (21.7)
Disease duration (months) 29.0 ± 1.2
SDAI 16.5 ± 1.9
Positive RF 11 (73.3)
Anti-CCP +ve 14 (93.3)
PFT FEV1 (% predicted) 62.1 ± 8.2
FVC (% predicted) 60.7 ± 0.9
TLC (% predicted) 70.0 ± 10.4
DLCO (% predicted) 59.4 ± 7.2
RA: rheumatoid arthritis, Gp1: patients on methotrexate, Gp2: patients o
activity index, RF: rheumatoid factor, CCP: citrullinated peptide. PFT: p
volume capacity, TLC: total lung capacity, DLco: diffusion capacity of ca
values are signiﬁcant at p< 0.05.may delay the progression to end-stage lung disease.
Diagnosis can be difﬁcult since patients are unlikely to report
dyspnea due to the decrease in physical activity with advanced
arthritic symptoms. Recently, there has been increasing recog-
nition of the importance of respiratory disease in patients
with rheumatoid arthritis. Notably, interstitial lung disease is
the only complication of RA increasing in prevalence and
accounts for approximately 6% of all RA deaths [21].
Our results revealed that 38.3% (23/60) of all included RA
patients had subclinical RA-ILD, while 61.7% (37/60) did not
have ILD (RA-no ILD). All RA-ILD cases had high-
resolution CT abnormalities characteristic of ILD despite
lacked chest manifestations. However, only 16 patients
(26.7%) had abnormal PFT and 12 (20%) had abnormal chest
radiography. Accordingly, normal chest examination, CXR,
PFT report cannot exclude ILD in patients with RA and we
are still in need for HRCT. Furthermore, abnormalities on
chest examination, PFTs with restrictive changes or chest X-
rays should prompt physicians to request a chest HRCT scan.
In our study, based on comparative analysis of clinical, labora-
tory and functional variables between RA-ILD and RA-no
ILD patients, long-standing disease with mean articular dura-
tion more than 50 months carries a signiﬁcant risk for ILD.
Other variables as age, gender, smoking, disease activity, or
RF seropositivity were not signiﬁcant risk factors for develop-
ment of RA-ILD. In the study of Gochuico et al. [22], chest
HRCT identiﬁed preclinical ILD in 21/64 (33%) asymptomatic
RA patients. They found that physical examination and PFT
measurements were not sensitive methods of detecting preclin-
ical ILD, however, they observed that the history of smoking
could be a potential risk factor for its development.
Karazincir et al. [23] also, investigated the pulmonary involve-
ment by HRCT in 25 RA patients who are asymptomatic and
lifelong non-smoker, Chest X-ray, PFT and HRCT ﬁndings
showed 12%, 16% and 48% abnormalities respectively. They
found no signiﬁcant correlation between HRCT ﬁndings and
disease activity, RF positivity, PFT results and disease dura-
tion. In the study of Chen et al. [24] the overall prevalence
of radiologically deﬁned RA-ILD in RA patients was high
(61%) though the frequency of clinically evident ILD was onlyune proﬁle and PFT between RA patients with and without ILD.
60)
) No-ILD p
Gp2 (n= 8) n= 37 (61.7%)
42.1 ± 1 50 ± 2.5 >0.05
6:3 (1.7:1) 29:8 (3.6:1) >0.05
3 (37.5) 9 (24.3) >0.05
26.1 ± 4.3 11.1 ± 8.0 <0.05
13.0 ± 4.0 12.7 ± 6.4 >0.05
4 (50) 14 (37.8) >0.05
5 (62.5) 18 (48.7) >0.05
65.1 ± 11.7 90.0 ± 17.2 <0.05
63.0 ± 5.6 89.4 ± 1.5 <0.05
72.1 ± 10.7 87.9 ± 11.3 <0.05
60.4 ± 8.0 88.0 ± 2.2 <0.05
n NSAIDs only, ILD: interstitial lung disease, SDAI: simple disease
ulmonary function test, FEV: forced expiratory volume, FVC: forced
rbon monoxide. Results are presented as mean ± SD or n (%). Bold
Table 5 Predictive factors for ILD in RA patients in the
multinomial logistic regression model.
Predictive factors (independent
variables)
Relative risk
ratio (95% CI)
p
Age (>60 years) 4.87 (1.89–10.4) <0.001
Gender 1.56 (0.66–4.07) >0.05
Smokers (>10 pack-years) 2.44 (0.70–10.2) >0.05
Disease duration (month) 7.67 (3.25–16.6) <0.001
SDAI 1.41 (0.29–5.02) >0.05
Methotrexate 2.16 (1.01–4.87) >0.05
RF (P100 U/ml) 3.15 (1.42–7.91) <0.05
Anti-CCP (P90 U/ml) 3.60 (1.84–8.07) <0.05
PFT FVC (<80%) 3.98 (1.12–5.26) <0.05
TLC (<80%) 1.49 (1.05–2.13) >0.05
DLCO (<50%) 1.33 (0.18–2.95) >0.05
SDAI: simple disease activity index, RF: rheumatoid factor, CCP:
citrullinated peptide. PFT: pulmonary function test, FEV: forced
expiratory volume, FVC: forced volume capacity, TLC: total lung
capacity, DLco: diffusion capacity of carbon monoxide. Bold val-
ues are signiﬁcant.
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higher disease activity represent risk factors for the develop-
ment of RA-ILD.
In this study we revealed that spirometry alone may be an
inadequate screening tool for subclinical ILD, and early func-
tional changes could be achieved with a complete set of PFTs
with lung volumes and DLCO to establish the diagnosis. Our
study showed that patients with subclinical ILD had signiﬁ-
cant reductions in DLCO compared with those without.
Similar results were found by Diaz de Leon et al. [25] and com-
parable ﬁndings were also present in a Japanese lung cancer
screening study [26], which demonstrated that subclinical
ILD was associated with a signiﬁcant decline in DLCO.
The ﬁrst-line DMARD in RA is MTX. However, serious
toxicity from MTX may affect the lungs, liver, and bone mar-
row. In our study, we found that 25% of RA patients on MTX
had RA-ILD in comparison to 13.3% of those patients on
NSAIDs only. Additionally, patients on MTX had more
HRCT abnormalities than those in group 2, however this dif-
ference was not signiﬁcant. Ground glass opacities and septal
thickening were the most common (80.5% and 66.7% respec-
tively), while honeycombing was observed in 62.7% of RA-
ILD patients. We found also a non-signiﬁcant difference in
PFT between RA patients on MTX and those not; the proba-
bility that the changes may be related to the lung disease asso-
ciated with RA rather than to methotrexate therapy cannot be
excluded.
Several studies agreed with our results; Zou et al. [27], stud-
ied 110 Chinese RA patients (79 women and 31 men) and ILD
was found in 47 (42.73%) according to the HRCT, however
honeycombing and subpleural nodules were more common
in patients on MTX. A study done by Gochuico et al. [22]
identiﬁed preclinical ILD in 21/64 patients (33%) having RA
by HRCT. They concluded that treatment using MTX may
be a risk factor for progression of preclinical ILD. Pappase
et al. [28] studied 158 RA patients and found that 7.6% had
PFT abnormalities consistent with restrictive lung disease.
Notably, the majority of patients (68%) were receiving
MTX. On the other hand, Dawson et al. [29] have reported
an interesting study concerning the chronic pulmonary effectsof MTX in RA patients there was no evidence of an associa-
tion. Interestingly, in patients with pulmonary ﬁbrosis, MTX
did not cause any deterioration in pulmonary function over
a 2-yr period. In another study of Sathi et al. [30], MTX has
not been shown to accelerate the progression of underlying
ILD in RA [15].
In conclusion, subclinical lung involvement should always
be considered in RA patients particularly those on MTX.
Pulmonary function tests supported by HRCT are necessary
to improve the detection of ILD in asymptomatic RA patients.
Further studies evaluating the potential effect of MTX on pro-
gressive ILD associated with RA are needed.
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